Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. // The Lancet Rheumatology. – URL: https://www.sciencedirect.com/science/article/pii/S2665991326002547?dgcid=rss_sd_all
Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Rheumatology. https://www.sciencedirect.com/science/article/pii/S2665991326002547?dgcid=rss_sd_all
“Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.” The Lancet Rheumatology.
@article{article98508,
title = {Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial},
journal = {The Lancet Rheumatology},
url = {https://www.sciencedirect.com/science/article/pii/S2665991326002547?dgcid=rss_sd_all}
}